| Company Name: |
Jiangsu Vcare PharmaTech Co., Ltd.
|
| Tel: |
025-58741518 13327700685 |
| Email: |
sales@vcarepharmatech.com |
| Products Intro: |
Product Name:Tricyclo[3.3.1.13,7]decane-1-acetic acid, α-[[(1,1-diMethylethoxy)carbonyl]aMino]-3,5-dihydroxy-, (αS)- CAS:681282-72-4
|
|
| | Tricyclo[3.3.1.13,7]decane-1-acetic acid, α-[[(1,1-diMethylethoxy)carbonyl]aMino]-3,5-dihydroxy-, (αS)- Basic information |
| Product Name: | Tricyclo[3.3.1.13,7]decane-1-acetic acid, α-[[(1,1-diMethylethoxy)carbonyl]aMino]-3,5-dihydroxy-, (αS)- | | Synonyms: | (2S)-2-[(3R,5S)-3,5-dihydroxy-1-adamantyl]-2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid;(S)-2-((tert-butoxycarbonyl)amino)-2-(3,5-dihydroxyadamantan-1-yl)acetic acid;Saxagliptin Impurity 19;Boc-3,5-dihydroxy-1-adamantyl-L-glycine;(S)-2-((tert-butoxycarbonyl)amino)-2-((1r,3R,5S,7S)-3,5-dihydroxyadamantan-1-yl)acetic acid;(2S)-2-((tert-butoxycarbonyl)amino)-2-((3R,5S)-3,5-dihydroxyadamantan-1-yl)acetic acid;Saxagliptin Impurity 6 (Saxagliptin Impurity);Tricyclo[3.3.1.13,?7]?decane-?1-?acetic acid, α-?[[(1,?1-?dimethylethoxy)?carbonyl]?amino]?-?3,?5-?dihydroxy-?, (αS)?- | | CAS: | 681282-72-4 | | MF: | C17H27NO6 | | MW: | 341.4 | | EINECS: | | | Product Categories: | | | Mol File: | 681282-72-4.mol | ![Tricyclo[3.3.1.13,7]decane-1-acetic acid, α-[[(1,1-diMethylethoxy)carbonyl]aMino]-3,5-dihydroxy-, (αS)- Structure](CAS/20210111/GIF/681282-72-4.gif) |
| | Tricyclo[3.3.1.13,7]decane-1-acetic acid, α-[[(1,1-diMethylethoxy)carbonyl]aMino]-3,5-dihydroxy-, (αS)- Chemical Properties |
| Boiling point | 534.7±35.0 °C(Predicted) | | density | 1.406±0.06 g/cm3(Predicted) | | pka | 3.93±0.10(Predicted) |
| | Tricyclo[3.3.1.13,7]decane-1-acetic acid, α-[[(1,1-diMethylethoxy)carbonyl]aMino]-3,5-dihydroxy-, (αS)- Usage And Synthesis |
| Uses | Boc-3,5-dihydroxy-1-adamantyl-L-glycine is a reactant in the synthesis of Saxagliptin (S143500), a potent and selective reversible inhibitor of dipeptidyl peptidase-4, which is being developed for the treatment of type 2 diabetes. It is absorbed rapidly after oral administration and has a pharmacokinetic profile compatible with once daily dosing. |
| | Tricyclo[3.3.1.13,7]decane-1-acetic acid, α-[[(1,1-diMethylethoxy)carbonyl]aMino]-3,5-dihydroxy-, (αS)- Preparation Products And Raw materials |
|